AstraZeneca Reinforces Tagrisso as Backbone Therapy for EGFR-Mutated Lung Cancer

On March 25, 2025, AstraZeneca presented new clinical trial results at the European Lung Cancer Congress, highlighting the continued efficacy of Tagrisso (osimertinib) across various stages and treatment settings of EGFR-mutated non-small cell lung cancer (NSCLC). The findings reinforce Tagrisso’s role as a foundational therapy, both as a standalone treatment and in combination with other targeted therapies.

In the Phase III LAURA trial, Tagrisso demonstrated a trend toward improved overall survival in patients with unresectable Stage III EGFRm NSCLC following chemoradiotherapy. Median overall survival reached 58.8 months for patients treated with Tagrisso compared to 54.1 months for those on placebo.

Phase II results from the SAVANNAH and ORCHARD trials explored combination treatments for patients who experienced disease progression on first-line Tagrisso. SAVANNAH showed that combining Tagrisso with Orpathys (savolitinib) produced a 56% objective response rate in patients with high MET expression or amplification. Similarly, Tagrisso plus Datroway (datopotamab deruxtecan) in the ORCHARD trial demonstrated encouraging response rates and progression-free survival, especially at the higher dose.

Additionally, the FLAURA2 trial confirmed a strong progression-free survival benefit when Tagrisso was combined with chemotherapy in the first-line treatment of advanced EGFRm NSCLC, with median PFS exceeding two years regardless of pemetrexed maintenance duration.

These findings underscore Tagrisso’s clinical value across the treatment spectrum, from early-stage to advanced disease, and support AstraZeneca’s broader strategy of developing innovative, well-tolerated therapies to meet significant unmet needs in lung cancer care.